Cell Therapeutics (CTIC): Q2 EPS of -$0.28. As of June 30, the company had ~$14.8M in cash and...


Cell Therapeutics (CTIC): Q2 EPS of -$0.28. As of June 30, the company had ~$14.8M in cash and cash equivalents. European launch of Pixuvri is targeted for Q4. Steven E. Benner named Chief Medical Officer. Targets cut in net operating burn rate to an average of $4.5M/month for the rest of 2012 from $6.5M/month. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs